Ampliphi Biosciences Corp (APHB): Jeremy Curnock Cook , director of Ampliphi Biosciences Corp purchased 239,753 shares on Mar 16, 2015. The Insider buying transaction was disclosed on Apr 12, 2016 to the Securities and Exchange Commission. The shares were purchased at $4.12 per share for a total value of $564,753.75.
Currently the company Insiders own 1.02% of Ampliphi Biosciences Corp shares according to the proxy statements.Institutional Investors own 37.98% of Ampliphi Biosciences Corp shares.
AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery development and commercialization of phage therapeutics. The Company is engaged in identifying characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology drug engineering development and manufacturing to develop second-generation bacteriophage products. Its pipeline is based on the use of bacteriophages a family of viruses that infect only bacteria. The Company’s lead program is AmpliPhage-002 for the treatment of staphylococcus aureus (S. aureus) infections including methicillin-resistant staphylococcus aureus (MRSA). It also has two other product candidates in development: AmpliPhage-001 for the treatment of Pseudomonas aeruginosa (P. aeruginosa) lung infections in cystic fibrosis (CF) patients and AmpliPhage-004 for the treatment of clostridium difficile (C. difficile) infections.